02500 VENUS MEDTECH-B
- 5.620
- 0.0000.00%
VENUS MEDTECH-B News
Express News | China International Capital Corporation: The medical instruments Sector is expected to benefit from product upgrades and overseas exports in 2025.
Qiming Medical - B (02500) intends to appoint Gu Junhua as an independent non-executive director.
Qiming Medical-B (02500) announced that the board of directors has resolved to hold the second extraordinary general meeting of shareholders for the company in 2024...
Hong Kong stock concept tracking | Medical devices trade-in program attracts institutional attention, clear trend of market recovery.
"Trade-in" is accelerating in the field of medical devices, and various provinces are intensively issuing "feasibility announcements", "project approval announcements" and "tender procurement notices", injecting a dose of "cardiotonic" into the market.
Sudden Movement Spotlight | Biomedical Class B shares rose in the afternoon, LKYG-B up 30%, institutions bullish on sector further recovery space
Biomedical Class B shares rose in the afternoon, as of the time of publication, Lai Kai Medicine-B rose by 27.88%, to 7.89 Hong Kong dollars; YimingAngke-B rose by 17.91%, to 5.86 Hong Kong dollars; Yasheng Medicine-B rose by 5.74%, to 46.95 Hong Kong dollars.
There is no limit on price fluctuation, new stocks are being speculated! The pioneer of ultrasound submits an application for registration on the gem.
Cumulative dividends exceed 0.3 billion over 4 years.
VENUS MEDTECH-B: 2024 INTERIM REPORT
Venus Medtech Appoints CFO
Qiming Medical-B (02500.HK): Zhu Bing appointed as Chief Financial Officer.
Gelonghui, September 9th: Qiming Medical-B (02500.HK) announced that Zhu Bing has been appointed as the company's Chief Financial Officer, effective from September 9, 2024.
A Quick Understanding: Announcement of Key Findings in the Review of Funds Usage for Qiming Medical-B (02500)
The stock has been suspended from trading on the Main Board of the Stock Exchange of Hong Kong since November 23, 2023. During this period, active communication with the Stock Exchange of Hong Kong has been conducted and a series of measures have been taken to meet the five resumption guidance, in order to resume trading of the company as soon as possible. The latest announcement on September 2 provides further disclosure on the progress of the first item of the five resumption guidance by the Stock Exchange of Hong Kong.
Leading the new generation of ball expansion aortic valve replacement (TAVR) | The first two patients successfully implanted with Venus-Vitae SMART-ALIGN international multi-center key clinical
Hangzhou, September 4, 2024 /PRNewswire/ -- On August 30, 2024, Hangzhou Qiming Medical Instruments Co., Ltd. ("Qiming Medical", 02500.HK), China's leading comprehensive platform for innovative structural heart disease medical devices, announced that the first two patients of SMART-ALIGN international multicenter pivotal clinical trial for its self-developed next-generation transcatheter aortic valve replacement (TAVR) balloon expandable valve system Venus-Vitae were successfully implanted at Prince of Wales Hospital in Hong Kong.
Express News | China Securities Co.,Ltd. recommends focusing on investment opportunities in the medical device sector, and focusing on the direction and individual stocks with strong performance certainty.
Qiming Medical-B (02500.HK): Li Yue resigns as a shareholder representative supervisor.
On August 30th, Qiming Medical-B (02500.HK) announced that: (1) Ms. Li Yue has resigned as the shareholder representative supervisor of the company due to other matters, and her resignation will take effect upon the appointment of the new shareholder representative supervisor at the temporary shareholders' meeting to be held at an appropriate time; and (2) Ms. Shao Min has resigned as the employee representative supervisor and the chairman of the company's board of supervisors due to other matters, and her resignation will take effect upon the election of the new employee representative supervisor at the employee representative meeting to be held by the company on August 30, 2024. Mr. Zhang Changxi has been elected as the employee representative supervisor at the company's employee representative meeting. This election does not require shareholder approval. On the same day, the supervision
Qiming Medical -B (02500.HK) the interim net loss attributable to owners of the parent company is 0.206 billion yuan.
Guolonghui on August 30th announced that, as of June 30, 2024, in the six months, the group's revenue was 0.231 billion yuan, a decrease of 9.7% year-on-year. The revenue fluctuation was due to a slight decrease in product unit price. The attributable loss to the parent company was 0.206 billion yuan, compared to a loss of 0.35 billion yuan in the same period last year.
QM Medical-B (02500) announced its interim performance with a gross profit of 0.182 billion yuan, achieving multiple important milestones in global clinical research and development projects.
Qiming medical -B (02500) released the interim performance for the six months ended June 30, 2024, during which period the group...
VENUS MEDTECH-B: ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2024
Express News | China Securities Co., Ltd.: Focus on investment opportunities in the medical devices, high-value consumables, and IVD (in-vitro diagnostic) fields.
Express News | China Securities Co., Ltd.: Domestic equipment procurement demand awaits recovery, focusing on the growth logic of innovative large products.
The board of directors of Qiming Medical B (02500.HK) held a meeting on August 30th to review and approve the mid-term performance.
Qiming Medical-B (02500.HK) announced that the board of directors meeting will be held on Friday, August 30, 2024, to consider and approve the company and its subsidiaries' mid-term performance as of June 30, 2024, and its release, to consider recommending the distribution of mid-term dividends (if any), and to handle other matters.
VENUS MEDTECH-B: DATE OF BOARD MEETING
Goldman Sachs has lowered the target prices for medical-related stocks across the board in 'Dahang'. Investors are still concerned about the impact of anti-corruption measures.
Goldman Sachs released a report and lowered the target prices of medical-related stocks by an average of about 9% ahead of the second quarter and first half performance season. At the same time, the industry sales forecast for fiscal years 2024 to 2025 were lowered by 1% to 15% and 1% to 16%, respectively. The bank believes that investors will continue to pay attention to the potential impact of anti-medical corruption, recent procurement policy updates, and the potential stimulus of trade-in programs. Goldman Sachs' investment ratings and target prices for pharmaceutical stocks are listed as follows: Stock | Investment Rating | Target Price (HKD) Weigao Group (01066.HK) | Buy | 7.8 yuan -> 8.7 yuan Kangji Medical
No Data
